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Amyloid-b 1–42 (Ab42) oligomers are synaptotoxic
for excitatory cortical and hippocampal neurons
and might play a role in early stages of Alzheimer’s
disease (AD) progression. Recent results suggested
that Ab42 oligomers trigger activation of AMP-
activated kinase (AMPK), and its activation is
increased in the brain of patients with AD. We show
that increased intracellular calcium [Ca2+]i induced
by NMDA receptor activation or membrane depolar-
ization activates AMPK in a CAMKK2-dependent
manner. CAMKK2 or AMPK overactivation is suffi-
cient to induce dendritic spine loss. Conversely,
inhibiting their activity protects hippocampal neu-
rons against synaptotoxic effects of Ab42 oligomers
in vitro and against the loss of dendritic spines
observed in the human APPSWE,IND-expressing
transgenic mouse model in vivo. AMPK phosphory-
lates Tau on KxGS motif S262, and expression of
Tau S262A inhibits the synaptotoxic effects of Ab42
oligomers. Our results identify a CAMKK2-AMPK-
Tau pathway as a critical mediator of the synapto-
toxic effects of Ab42 oligomers.
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent form of dementia
affectingmore than 5million people in the United States and over
25 million people worldwide. This neurodegenerative disease
mainly affects people over 65 years old in its sporadic late-onset
form but can affect younger individuals in its genetically
inherited, early-onset form. AD is thought to be caused by
the abnormal accumulation of a 40- to 42-amino acid-long
amyloid-b (Ab) peptide derived from cleavage of the transmem-
brane protein amyloid precursor protein (APP). Amyloid-b 1-42
Ab42 has a strong ability to oligomerize to form diffusible dimers
and trimers as well as larger oligomers, which fibrillate to form
insoluble amyloid plaques, a major hallmark of AD. Intracellular
neurofibrillary tangles, the second histological hallmark of the
disease, are composed of hyperphosphorylated microtubule-
associated protein Tau. The molecular mechanisms linking Ab94 Neuron 78, 94–108, April 10, 2013 ª2013 Elsevier Inc.to Tau hyperphosphorylation as well as their relative contribution
to the pathophysiological mechanisms underlying AD progres-
sion are still poorly understood.
Reduction in density of excitatory synapses in the hippocam-
pus and cortex is an early abnormality detected in the brain of
patients with AD (Davies et al., 1987; Masliah et al., 2001;
Moolman et al., 2004). Analyses of transgenic mice expressing
mutations in APP found in families affected with early-onset AD
support these findings. For example, the J20 transgenic mouse
model (APPSWE,IND) shows clear signs of hyperexcitability, pro-
gressive loss of dendritic spines and excitatory synaptic connec-
tions (Jacobsen et al., 2006), and increased inhibitory synaptic
connectivity before the appearance of amyloid plaques (Mucke
et al., 2000; Palop et al., 2007). Soluble Ab42 oligomers
produced in vitro or extracted biochemically from the brains of
patients with AD have been shown to induce acute and rapid
synaptic loss (Jin et al., 2011; Lacor et al., 2004, 2007; Shankar
et al., 2007, 2008). Current model proposes that abnormal accu-
mulation of Ab42 oligomers induces early synaptotoxic effects
and progressive dendritic spine loss, whereas hyperphosphory-
lated Tau translocates from the axon to the dendrites and den-
dritic spines where it further reduces excitatory synaptic trans-
mission by activating a Fyn-dependent pathway (Hoover et al.,
2010; Ittner et al., 2010).
AMP-activated kinase (AMPK) is a heterotrimeric Serine/
Threonine protein kinase composed of one catalytic subunit
(encoded by a1 or a2 genes in mammals) and two regulatory
subunits, b (an adaptor subunit) and g (the AMP-binding sub-
unit), which are encoded by b1 or b2 genes and g1, g2, or
g3 genes, respectively (Alessi et al., 2006; Hardie, 2007;
Mihaylova and Shaw, 2011). AMPK is an important regulator
of cellular metabolism and functions as a metabolic sensor
(Mihaylova and Shaw, 2011). It is activated by various forms
of metabolic stress involving lowering of the AMP:ATP ratio
but can also be activated by other forms of cellular stress
such as exposure to reactive oxygen species (ROS) (reviewed
in Hardie, 2007). AMPK regulates a large number of biological
responses, including cell polarity, autophagy, apoptosis, and
cell migration (Williams and Brenman, 2008). Liver kinase B1
(LKB1, also called STK11 or Par4) is the main activator of
AMPK in most cell types (Hawley et al., 2003; Shaw et al.,
2004; Woods et al., 2003), acting by phosphorylating a single
Threonine residue within the T-activation loop of the kinase
domain of AMPK (residue T172). In addition to AMPK, LKB1
can activate a large family of AMPK-related kinases, including
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SAD-B and SAD-A, respectively), NUAK1/NUAK2 (also known
as ARK5 and SNARK, respectively), SIK1–SIK3 (for salt-
induced kinases), MARK1–MARK4 (for microtubule affinity-
regulated kinases), and SNRK (sucrose nonfermenting-related
kinase). These kinases are all controlled by phosphorylation
of the conserved T-activation loop Threonine residue, thereby
making LKB1 a master kinase for the AMPK-like kinase family
(Jaleel et al., 2005; Lizcano et al., 2004).
We previously reported that unlike in other cell types, LKB1 is
not the major activator of AMPK in immature neurons because
basal levels of activated AMPK remain unchanged in cortical
neurons upon cortex-specific conditional deletion of LKB1
(Barnes et al., 2007). On the other hand, several lines of evidence
suggest that in various neuronal subtypes, CAMKK2 can phos-
phorylate and activate AMPK (Anderson et al., 2008; Green
et al., 2011). Recently, two reports provided biochemical
evidence showing that Ab42 oligomers can activate AMPK
(Yoon et al., 2012) in a CAMKK2-dependent manner in neurons
(Thornton et al., 2011). Furthermore, activated AMPK seems
strongly enriched in tangle- and pretangle-bearing neurons in
patients with AD (Vingtdeux et al., 2011b), suggesting that
AMPK might play a role in AD progression (Salminen et al.,
2011). However, the role of the CAMMK2-AMPK pathway in
the etiology and/or the pathophysiology of AD is currently
unknown, although some studies have suggested that AMPK
activation in AD might provide protective effects by decreasing
Ab production/APP cleavage or increasing Ab clearance (Vingt-
deux et al., 2010, 2011a).
In the present study, we show that the CAMKK2-AMPK kinase
pathway plays a major role in mediating the early synaptotoxic
effects of Ab42 oligomers both in vitro and in vivo. Our results
suggest that the CAMKK2-AMPK kinase pathway represents a
target for therapeutic approaches to treat AD.
RESULTS
The CAMKK2-AMPK Kinase Pathway Is Required for the
Synaptotoxic Effects of Ab42 Oligomers In Vitro
To evaluate the function of the CAMKK2-AMPK pathway in AD,
we first confirmed that application of amyloid-b 1–42 (Ab42)
oligomers (Figure S1A available online), but not a peptide of
inverted sequence (INV42) on mouse cortical or hippocampal
neurons, triggers rapid (within 15 min) and also prolonged (up
to 24 hr) AMPK activation measured using the ratio between
pT172-AMPK to total AMPK (Figures 1A, 1B, S1B, and S1C).
The increase in AMPK activation triggered by Ab42 oligomers
is strongly attenuated by treatment with STO-609 (Figures 1A
and 1B), a specific inhibitor of CAMKK2 at the concentration
of 2.5 mM (Tokumitsu et al., 2002). Excitotoxicity due to overex-
citation of NMDA receptors (NMDARs) and increased intra-
cellular calcium levels have been implicated as a central
mechanism by which Ab42 oligomers induces synaptotoxicity
(Shankar et al., 2007). A role of NMDARs in AD is further
supported by the clinically beneficial effects of the partial
NMDAR antagonist memantine (De Felice et al., 2007). Further-
more, application of Ab42 oligomers is well documented to
induce a rapid and prolonged increase in intracellular calciumlevels through multiple mechanisms (Bezprozvanny and Matt-
son, 2008). Interestingly, we observed that extracellular signals
triggering increase in [Ca2+]i such as membrane depolarization
(which activates voltage-gated calcium channels, VGCCs)
or NMDA (which activates calcium-permeable ionotropic
glutamate NMDARs) both robustly activate AMPK, which can
be blocked by using the CAMKK2 inhibitor STO-609 (Figures
1C–1F).
Based on these results, we tested if activating the CAMKK2-
AMPK kinase pathway would mimic the cellular consequences
of Ab42 oligomer treatment in hippocampal and cortical
neurons. As previously reported by Lacor et al. (2004, 2007),
Shankar et al. (2007), and Wei et al. (2010), incubation of hip-
pocampal neurons cultured for 21 days in vitro (DIV) with
Ab42 oligomers (1 mM) for 24 hr induced a significant reduction
in dendritic spine density compared to control (neurons treated
with INV42) (Figures 1G, 1H, and 1L). At this dose and duration,
Ab42 oligomers did not induce loss of neuronal viability (Fig-
ure S2), strongly arguing that the synaptotoxic effects are not
a secondary consequence of impairing neuronal survival.
Next, we tested if CAMKK2 and AMPKa overexpression was
sufficient to mimic the synaptotoxic effects of Ab42 oligomers.
As shown in Figures 1I–1K0 and quantified in Figures 1L and
1M, our results show that the overexpression of CAMKK2,
AMPKa1, or AMPKa2 induced a significant reduction in spine
density of the same magnitude as Ab42 oligomer application
within 24 hr. Finally, application of the AMP-like small molecule
AICAR, a potent activator of AMPK, induced a dose-depen-
dent reduction in spine density within 24 hr on hippocampal
neurons in culture (Figures 1N and 1O). A comparable syn-
aptotoxic effect could also be observed upon activation of
AMPK using metformin, which broadly activates AMPK by
inducing a metabolic stress involving reduction of ATP level
and conversely increase in ADP/AMP level (Hardie, 2006;
Hawley et al., 2010) (Figures 1P and 1Q). Finally, application
of a more specific AMPK activator, A-769662, induced a signif-
icant, dose-dependent decrease in spine density within 24 hr
(Figures 1P and 1Q). Taken together, these experiments
demonstrate that overactivation of CAMKK2 or AMPK is suffi-
cient to mimic the synaptotoxic effects induced by Ab42
oligomers.
We next tested if the CAMKK2-AMPK pathway is required
for the synaptotoxic effects induced by Ab42 oligomers in
hippocampal neurons in vitro. We first took advantage of con-
stitutive knockout (KO) mouse lines for CAMKK2 (Ageta-Ishihara
et al., 2009) and AMPKa1 (Viollet et al., 2003) and treated
dissociated neuronal cultures isolated from control (CAMKK2+/+
and AMPKa1+/+, respectively) or KO mice (CAMKK2/ and
AMPKa1/) at 21 DIV with INV42 or Ab42 oligomers (1 mM for
24 hr) (Figures 2A and 2C). Quantitative analysis indicated that
CAMKK2 null and AMPKa1 null neurons do not show a signifi-
cant reduction of spine density following Ab42 oligomer treat-
ment (Figures 2B and 2D). Second, pharmacological inhibition
of CAMKK2 activity using application of the inhibitor STO-609
in culture prevented the decrease of spine density induced by
Ab42 oligomer application in vitro (Figures 3A and 3B).
Although the experiments presented above indicated that
CAMKK2 and AMPKa kinases are required to mediate theNeuron 78, 94–108, April 10, 2013 ª2013 Elsevier Inc. 95
Figure 1. Ab42-Dependent and Activity-Dependent Activation of the CAMKK2-AMPK Kinase Pathway in Cortical Neurons
(A–F) Primary cortical neurons isolated from E18.5 mouse embryos were cultured for 21 DIV and then treated with Ab42 oligomers (1 mMmonomer equivalent for
24 hr) or INV42 (1 mM for 24 hr), KCl (20mM for 15min), and NMDA (50 mM for 15min), in absence (CONT, control vehicle only) or presence of STO-609 (2.5 hr prior
to treatment; 2.5 mM). Activation of AMPK was assessed by western blotting using the phospho-specific T172-AMPKa antibody and total AMPKa antibody (n = 6
experiments). Histograms in (B), (D), and (F) represent mean with SEM.
(legend continued on next page)
Neuron
CAMKK2-AMPK Kinase Pathway and Alzheimer’s Disease
96 Neuron 78, 94–108, April 10, 2013 ª2013 Elsevier Inc.
Figure 2. CAMKK2 and AMPKa1 Are
Required for Ab42 Oligomer-Induced Spine
Toxicity In Vitro
(A and C) Representative images of secondary
dendritic segments of hippocampal neurons
obtained from (A) control (CONT, CAMKK2+/+
or CAMKK2+/) or CAMKK2 KO, and (C) WT
(AMPKa1+/+) or AMPKa1 KO animals treated with
Ab42 oligomers or INV42 (1 mM for 24 hr). Hippo-
campal neurons were transfected with pCAG-
EGFP plasmid at 11 DIV for spine visualization and
treated at 20 DIV for 24 hr prior to fixation.
(B and D) Neurons deficient for CAMKK2 (B) or
AMPKa1 (D) were resistant to spine loss induced
by Ab42 oligomer exposure. Spine density was
measured on 37–58 dendritic segments per con-
dition. Box plots represent data distribution (box
25th–75th percentiles, bars 10th–90th percentiles
with central bar representing median).
Statistical analysis was performed using Kruskal-
Wallis test followed by Dunn’s posttest in (B) and
(D). ***p < 0.001; ****p < 0.0001. Scale bars, 1 mm (A
and C).
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conclude if CAMKK2 acts pre- or postsynaptically, or even indi-
rectly by acting on nonneuronal cells such as astrocytes, which
are critically important for synapse formation and maintenance
(Eroglu and Barres, 2010). Therefore, we used a third approach
where CAMKK2 function was inhibited in a cell-autonomous
manner using low transfection efficiency of dominant-negative
(kinase-dead, KD) forms of CAMKK2 (CAMKK2 KD) in wild-
type (WT) hippocampal neuron cultures. This experiment re-
vealed that cell-autonomous inhibition of CAMMK2 function pre-
vents the reduction of spine density induced by Ab42 oligomer
application (Figures 3C and 3D). Similarly, cell-autonomous inhi-
bition of AMPK catalytic activity by expression of a dominant-
negative (KD) form of AMPKa (AMPKa2 KD) also abolished the
reduction of spine density induced by Ab42 oligomers (Figures
3E and 3F). Importantly, neither CAMKK2 KD nor AMPKa2 KD(G–K0) Morphology of hippocampal neurons and their dendritic segments (secondary branches) treated at 21 D
for 24 hr) or INV42 (1 mM for 24 hr), or overexpressing CAMKK2, AMPKa1, or AMPKa2 (transfection at 15 D
(L and M) Application of Ab42 oligomers induced a significant reduction in dendritic spine density compared t
or AMPKa2 (M) resulted in dendritic spine loss compared to control neurons expressing GFP only.
(N–Q) Hippocampal neurons treated at 21 DIV for 24 hr with compounds that activate AMPK such as AICAR
loss. Spine density was measured on 16–61 dendritic segments per condition.
Box plots in (L), (M), (O), and (Q) represent data distribution (box 25th–75th percentiles, bars 10th–90th percentil
analysis was performed using ANOVA test followed byDunnett posttest in (B), (D), (F), and (O) and Kruskal-Wal
**p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant p > 0.05. Scale bars, 5 mm (G–K) and 2 mm (G0, H0
Neuron 78, 94–overexpression alone had any significant
effect on spine density per se (Figures
3C–3F). These results strongly support
the notion that the synaptotoxic effects
of Ab42 oligomers require activation of
the CAMKK2-AMPK kinase pathway in
hippocampal neurons.We next assessed the protective effects of blocking CAMKK2
following Ab42 oligomer application using a functional approach.
To do this, we performed whole-cell patch-clamp recordings of
pharmacologically isolated AMPA-type miniature excitatory
postsynaptic currents (mEPSCs) in hippocampal cultures at 18
DIV. As previously shown by Shankar et al. (2007) and Wei
et al. (2010), application of Ab42 oligomers (1 mM for 24 hr)
induced a significant reduction in mEPSC frequency (manifested
as an increase in interevent intervals) compared to control
(INV42) (Figures 3G and 3H). Importantly, overexpression of a
KD version of CAMKK2 did not affect basal mEPSC frequency
but abolished the decrease in mEPSC frequency induced by
Ab42 oligomer application (Figures 3G and 3H). None of the
treatments had any significant effect on AMPA receptor-
mediated mEPSC amplitude (Figure 3I). These results demon-
strate that the CAMKK2-AMPK kinases are critical for the earlyIV with Ab42 oligomers (1 mMmonomer equivalent
IV and visualization at 22 DIV).
o INV42. Overexpression of CAMKK2 (L), AMPKa1,
, metformin, or A-769662 also induced rapid spine
es with central bar representing median). Statistical
lis with Dunn’s posttest in (L), (M), and (Q). *p < 0.05;
, I0, J0, K0, N, and P). See also Figures S1 and S2.
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Figure 3. Inhibition of CAMKK2 or AMPK Activity Blocks the Synaptotoxic Effects of Ab42 Oligomers in Hippocampal Neurons In Vitro
(A and B) Representative images of dendritic segments (A) and spine density quantification (B) of 21 DIV hippocampal neurons treated at 20 DIV with the CAMKK2
inhibitor STO-609 (2.5 mM) or DMSO (control) 2 hr prior to Ab42 oligomer or INV42 application (1 mM for 24 hr). Neurons treated with STO-609 were resistant to
spine loss induced by Ab42 oligomers.
(C and D) Representative images of dendritic segments (C) and quantification of spine density (D) of hippocampal neurons at 21 DIV expressing a KD version of
CAMKK2 (K194A, transfected at 15 DIV), which significantly reduces the synaptotoxic effects of Ab42 oligomers.
(E and F) Representative images of dendritic segments (E) and quantification of spine density (F) of neurons that express a KD version of AMPKa2 (K45A,
transfected at 15 DIV), which blocks the synaptotoxic effects of Ab42 oligomers. Each condition is quantified from at least three independent experiments (19–151
dendritic segments quantified per condition).
(G) Representative traces of mEPSCs recorded from 18 to 19 DIV hippocampal neurons expressing CAMKK2 KD or control vector (transfected at 11 DIV) and
treated with Ab42 oligomers or INV42 (1 mM for 24 hr).
(H and I) Inter-mEPSC intervals (H) and mEPSC amplitudes (I) were quantified from 16 to 21 cells per condition (obtained from six independent experiments).
Expression of CAMKK2 KD prevented the increase in inter-mEPSC interval induced by Ab42 oligomers. There was no significant difference in mEPSC amplitude
among the different conditions. Histograms represent mean with SEM.
Box plots in (B), (D), and (F) represent data distribution (box 25 th–75th percentiles, bars 10 th–90th percentiles with central bar representing median).
Statistical analysis was performed using ANOVA test followed by Dunnett’s posttest in (B) and (F) and Kruskal-Wallis test followed by Dunn’s posttest in (D), (H),
and (I). *p < 0.05; **p < 0.01; ****p < 0.0001. Scale bars, 1 mm (A, C, and E).
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synaptic maintenance.
The CAMKK2-AMPK Kinase Pathway Is Required for the
Dendritic Spine Loss in the APPSWE,IND Mouse Model
In Vivo
Next, we tested the protective effects of inhibiting the CAMKK2-
AMPK pathway in a context where neurons are exposed to
Ab42 oligomers derived from pathological human APP in vivo.
We used a well-validated transgenic mouse model (J20 trans-
genic mice) overexpressing a pathological form of human APP
carrying mutations present in familial forms of AD (APPSWE,IND)
under PDGFb promoter. These transgenic mice develop early
signs of excitatory synaptotoxicity prior to amyloid plaque
appearance (Mucke et al., 2000; Palop et al., 2007). We verified
that this mouse model shows increased Ab expression in the
hippocampus (Figure 4A) and, in particular, increased APP and
soluble Ab both at 3 months (Figures 4B and 4C) and 8–
12 months (Figure S3) compared to control littermates at the
same ages. We could already detect a significant increase in
activated pT172-AMPK in the cytosolic fraction of 4-month-old
hippocampal tissue lysate from J20 transgenic mice compared
to control littermates (Figures 4D and 4F). The increased AMPK
activation is maintained in the hippocampus of older mice (8–
12 months old; Figures 4E and 4G) compared to age-matched
control littermates.
In order to block the CAMKK2-AMPK signaling pathway in
hippocampal neurons, we performed in utero electroporation
at embryonic day (E)15.5, targeting specifically hippocampal
pyramidal neurons located in CA1–CA3 regions of control or
J20 transgenic mice (Figure 4H). Following long-term survival
until 3 months postnatally, this approach allows optical isolation
of single dendritic segments of pyramidal neurons in CA3 by
confocal microscopy (Figure 4I) and to perform quantitative
assessment of spine density. This analysis revealed that spine
density of pyramidal neurons was already significantly
decreased in the J20 mice at 3 months postnatally compared
to control littermates (Figures 4J and 4K). Importantly, overex-
pression of a KD version of CAMKK2 or a KD version of AMPKa2
prevented the reduction of spine density observed in CA3 pyra-
midal neurons of 3-month-old J20 transgenic mice without
affecting spine density in the WT control mice (Figures 4J
and 4K). These results demonstrate that the activation of the
CAMKK2-AMPK kinase pathway is required to mediate the
synaptotoxic effects observed in the APPSWE,IND mouse model
in vivo.
AMPKa1 Phosphorylates Tau on S262 in Response
to Ab42 Oligomers
Plaques of Ab and tangles formed by hyperphosphorylated
forms of the microtubule-binding protein Tau are the two histo-
pathological signatures found in the brains of patients with AD.
Although both Ab and Tau have been extensively studied inde-
pendently with regard to their separate modes of toxicity,
recent results have shed light on their possible interactions
and synergistic effects during AD progression. For example,
Tau-deficient mice are less susceptible to Ab toxicity than con-
trol mice (Roberson et al., 2007). Recent results have shownthat AMPK is a potent Tau kinase (Thornton et al., 2011). In
order to reconstitute a biochemical pathway triggering AMPK
activation, we expressed a GFP-tagged version of Tau and
AMPKa in HeLa cells, which are naturally deficient for LKB1
(Hawley et al., 2003). In this model, AMPK can be specifically
activated by reintroducing its upstream activator LKB1. This
experiment confirmed that AMPK phosphorylates the well-
characterized KxGS motif on Tau Serine 262 (S262) residue
(Figure 5A). When coexpressed in cell lines, both LKB1 (coex-
pressed with its coactivator STRAD) and CAMKK2 are potent
activators of AMPK, although we observed that CAMKK2 was
significantly more potent in phosphorylating AMPK on T172
than LKB1 or CAMKK1 (Figure 5B). Furthermore, direct activa-
tion of AMPK using the AMP analog AICAR triggered a dose-
dependent increase of Tau phosphorylation of S262 in cortical
neurons (Figures 5C, 5D, and S4), a treatment that induces a
dose-dependent reduction in spine density (Figures 1N and
1O). The microtubule-associated protein Tau is phosphorylated
in multiple sites (Mandelkow and Mandelkow, 2012), and anal-
ysis of six well-characterized phosphorylation sites revealed
that following 24 hr treatment with AICAR, phosphorylation of
Tau on S262 is significantly increased in a dose-dependent
manner but that other sites are either unchanged (for example,
the other KxGS motif on S356, as well as S396, S422) or
decreased (S202/T205, S404) (Figures S4A and S4B). This
observation suggests that S262 is an important target of
AMPK, and phosphorylation of this site might underlie AMPK-
induced spine loss.
Preventing Tau Phosphorylation on S262 Protects
Hippocampal Neurons from the Synaptotoxic Effects
of Ab42 Oligomers In Vitro and the Dendritic Spine Loss
Observed in the APPSWE,IND Mouse Model In Vivo
Previous studies in Drosophila suggested that overexpression
of AMPK-related member PAR-1/MARK2 induced neurotoxicity
through phosphorylation of Tau in the microtubule-binding
domains on S262 and S356 and that phosphorylation of these
sites played an initiator role in the pathogenic phosphorylation
process of Tau (Nishimura et al., 2004). Given the importance
of phosphorylation of S262 as a ‘‘priming’’ site (Biernat et al.,
1993) and the recent implication of Tau in the synaptotoxic
effects of Ab42 oligomers (Ittner et al., 2010; Roberson et al.,
2007), we wanted to test if expression of a form of Tau that
cannot be phosphorylated on S262 could exert a protective
effect in the context of Ab42 oligomer-induced synaptotoxicity
in cultured hippocampal neurons. Expression of Tau S262A
abolished the loss of spines induced by Ab42 oligomers (Figures
5E–5H), although its expression in control neurons did not have
any effect on spine density. By contrast, expression of Tau WT
or a phospho-mimetic version of Tau on S262 (Tau S262E) re-
sulted in spine loss in control condition, and the WT form of
Tau was unable to prevent the synaptotoxic effects of Ab42
oligomers. Finally, the nonphosphorylatable form of Tau on
S356 (S356A) displayed similar protective effects as Tau
S262A mutant, indicating that the phosphorylation of these
two serine residues in the microtubule-binding domains plays
a critical role in mediating the synaptotoxic effects of Ab42
oligomers.Neuron 78, 94–108, April 10, 2013 ª2013 Elsevier Inc. 99
Figure 4. Inhibition of CAMKK2 or AMPK Activity Blocks the Synaptotoxic Effects of Ab42 Oligomers in Hippocampal Neurons In Vivo
(A) Human APP and Ab oligomers were detected by immunohistochemistry with the 6E10 antibody in the J20 transgenic mice (but not control littermates) as early
as 3 months.
(legend continued on next page)
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S262 in vivo, we performed in utero electroporation of Tau
S262A construct in E15.5 WT and J20 embryos and analyzed
spine density of CA3 hippocampal pyramidal neurons in the
adult mice at 3 months (Figures 5I and 5J). Tau S262A slightly
decreased spine density in WT animals compared to control
vector, suggesting that phosphorylation of Tau on S262 plays
a role in spine development. Nevertheless, Tau S262A adminis-
tration was able to prevent spine loss induced by Ab oligomers
in the J20 animals to a level similar to WT animals electroporated
with the same Tau mutant construct (Figure 5J). These results
strongly suggest that phosphorylation of Tau on S262 mediates
the synaptotoxic effects observed in the APPSWE,IND mouse
model in vivo.
Preventing Tau Phosphorylation on S262 Protects
Hippocampal Neurons from Spine Loss Induced by
AMPKa1 Activation
To determine whether phosphorylation of Tau on S262 is
required for AMPK-induced spine loss, we treated hippocampal
neurons expressing Tau S262Amutant with the AMPK activators
metformin or AICAR for 24 hr in vitro (Figures 6A and 6B).
Although metformin and AICAR treatments resulted in a marked
decrease in spine density, neurons expressing Tau S262A
mutant were insensitive to metformin or AICAR treatment and
did not show a significant decrease in spine density.
To further demonstrate the involvement of AMPK in Tau phos-
phorylation, we performed long-term cultures of cortical neurons
isolated from individual AMPKa1+/+ and AMPKa1/ mouse
littermates, treated them with Ab42 oligomers or INV42, and as-
sessed Tau phosphorylation on S262. First, we could validate
that Ab42 oligomers increased AMPK activation detected by
pT172-AMPK/total AMPK ratio (Figures 6C and 6D). AMPKa1
seems to be the major isoform of AMPKa responding to Ab42
oligomers in cortical neurons because (1) AMPKa1 null neurons
show a drastic reduction in total AMPK levels detected by an
antibody recognizing both AMPKa1 and AMPKa2, and (2)
AMPKa1 null neurons do not show increased AMPK activation
following Ab42 oligomer application (Figures 6C and 6D).
Finally, in the same neurons, treatment with Ab42 oligomers
led to a slight, albeit reproducible and significant, increase in
Tau phosphorylation on S262 in control AMPKa1+/+ but not in(B and C) The hippocampus from 3-month-old WT and J20 mice was dissected,
Ab levels by western blotting with the 6E10 antibody. The J20 mice presented
genotype).
(D–G) The hippocampi of 4-month-old (D and F) and 8- to 12-month-old (E and G
AMPK activity for hippocampi isolated from individual mice was assessed by wes
the cytosolic fraction of the J20 transgenic mice at both ages compared to litter
(H and I) Inhibition of CAMKK2 or AMPKa activity in hippocampal pyramidal neuro
CAMKK2 KD and AMPKa2 KD encoding plasmids in E15.5WT and J20mouse em
in I) of basal dendrites (in stratum oriens) of CA3 pyramidal neurons in 3-month-
(J and K) Expression of CAMKK2 KD or AMPKa2 KD blocked the reduction of
(33–53 dendritic segments from three to six animals per condition). Expression o
spine density in control mice. Box plots in (K) represent data distribution (box 2
median).
Histograms in (C), (F), and (G) represent mean ± SEM. Statistical analysis was perfo
was used to compare specific groups toWT-GFP (in blue) and to J20-GFP (in red)
and 200 mm (A). See also Figure S3.AMPKa1 null hippocampal neurons (Figures 6E and 6F), sug-
gesting that AMPKa1 mediates the phosphorylation of Tau on
S262 induced by Ab42 oligomers in hippocampal neurons.
DISCUSSION
Loss of synapses begins during the early stages of AD and pro-
gressively affects neuronal network activity, leading to cognitive
dysfunction (Coleman and Yao, 2003; Palop and Mucke, 2010;
Terry et al., 1991). In vitro and in vivo studies have demonstrated
that Ab oligomers are contributing to early synapse loss (Hsia
et al., 1999; Hsieh et al., 2006; Lacor et al., 2007; Mucke et al.,
2000; Shankar et al., 2007), whereas recent studies support
Tau as one of the mediators of Ab toxicity in dendrites (Ittner
et al., 2010; Roberson et al., 2007, 2011). However, our under-
standing of the molecular mechanisms linking Ab oligomers
and Tau synaptotoxicity in dendritic spines remains incomplete.
Here, we report that (1) AMPK is overactivated in hippocampal
neurons upon application of Ab42 oligomers, and this activation
is dependent on CAMKK2; (2) CAMKK2 or AMPK activation is
sufficient to induce dendritic spine loss in hippocampal neurons
in vitro and in vivo; (3) Ab-mediated activation of AMPK induces
the phosphorylation of Tau on residue S262 in the microtubule-
binding domain; and (4) inhibition of either CAMKK2 or AMPK
catalytic activity, or expression of a nonphosphorylatable form
of Tau (S262A), blocks Ab42 oligomer-induced synaptotoxicity
in hippocampal neurons in vitro and in vivo.
AMPK is an important homeostatic regulator and is activated
by various forms of cellular and metabolic stresses (Mihaylova
and Shaw, 2011; Shaw et al., 2004). Oxidative stress such as
elevation of ROS can activate AMPK through a mechanism
that is still unclear (reviewed in Hardie, 2007). Because part of
the neuronal toxicity induced by Ab is thought to involve
increased ROS production (Schon and Przedborski, 2011),
future experiments should test if AMPK function during
Ab-mediated neurodegeneration requires the ability of ROS to
activate AMPK.
In the brain, AMPK activity is increased in response to meta-
bolic stresses such as ischemia, hypoxia, or glucose deprivation
(Culmsee et al., 2001; Gadalla et al., 2004; Kuramoto et al., 2007;
McCullough et al., 2005) and is abnormally elevated in several
human neurodegenerative disorders, including AD and otherlysed, and the crude homogenate was processed to assess human APP and
increased APP and Ab levels compared to WT littermates (n = 3 animals per
) WT and J20 mice were dissected and processed for cytosolic fractionation.
tern blotting with pT172-AMPKa antibody, which was significantly increased in
mate controls (n = 7–10 animals per genotype at both ages).
ns of the CA3 region (arrow in H) was performed by in utero electroporation of
bryos. Dendritic spine density was quantified in the collateral processes (arrow
old transfected animals.
spine density observed in CA3 pyramidal neurons of 3-month-old J20 mice
f CAMKK2 KD (but not AMPKa2 KD) induces a slight but significant increase in
5 th–75th percentiles, bars 10 th–90th percentiles with central bar representing
rmed usingMann-Whitney U test in (C), (F), and (G). In (K), Mann-Whitney U test
. *p < 0.05; **p < 0.01; ****p < 0.0001. Scale bars, 2 mm (J), 50 mm (I), 100 mm (H),
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Figure 5. Phosphorylation of Tau on S262 Is Required for the Synaptotoxic Effects of Ab Oligomers In Vitro and In Vivo
(A) Cotransfection of WT forms of AMPKa1 or a2 together with LKB1 is sufficient to trigger Tau phosphorylation on S262 residue in HeLa cells. Western blot on
25 mg of protein lysate with the indicated antibodies.
(B) Upstream kinases LKB1, CAMKK1, and CAMKK2 display various abilities to phosphorylate AMPK upon expression in HEK293T cells. Western blot on 25 mg of
protein lysate with the indicated antibodies.
(C and D) AICAR treatment of cortical neurons at 21 DIV for 24 hr increased phosphorylation of Tau at epitope S262 compared to control (CONT, vehicle only).
Histograms in (D) represent mean with SEM.
(E–H) Hippocampal neurons were transfected at 11 DIV with constructs for different versions of Tau, treated with Ab42 oligomers or INV42 at 20 DIV (1 mM for
24 hr), and spine density was assessed at 21 DIV. (E and F) Overexpression of WT Tau or its phospho-mimetic S262E version decreased spine density, whereas
the nonphosphorylatable forms S262A and S356A had no effect. (G and H) Overexpression of mutant Tau S262A or S356A blocked oligomer-induced spine
toxicity, whereas the WT form of Tau had no protective effects (n = 16–71 segments per condition).
(I and J) Tau S262A was expressed in hippocampal pyramidal neurons of the CA3 region following in utero electroporation of E15.5 WT and J20 mouse embryos.
Tau S262A expression induced amild but significant decrease in spine density in WT animals but lessened the synaptotoxic effects of Ab oligomers compared to
J20 animals electroporated with control vector (19–53 dendritic segments from three to six animals per condition; compare figures with Figure 4J).
Box plots in (F), (H), and (J) represent data distribution (box 25 th–75th percentiles, bars 10 th–90th percentiles with central bar representing median). Statistical
analysis was performed using Mann-Whitney U test in (C) and ANOVA test followed by Dunnett’s posttest in (F) and (H). In (J), Mann-Whitney U test was used to
compare specific groups toWT-GFP (in blue) and to J20-GFP (in red). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Scale bars, 1 mm (E andG) and 2 mm (I). See
also Figure S4.
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Figure 6. Phosphorylation of Tau on S262
by AMPKa1 Is Required for the Synapto-
toxic Effects of Ab42 Oligomers
(A and B) Hippocampal neurons were transfected
at 11 DIV with control (GFP) or Tau S262A
construct, treated with AMPK activator metformin
or AICAR (100 mM) at 20 DIV for 24 hr, and spine
density was assessed at 21 DIV. Overexpression
of Tau S262A prevented the loss of spines induced
by AMPKa overactivation (16–28 dendritic seg-
ments per condition). Box plots in (B) represent
data distribution (box 25 th–75th percentiles, bars
10 th–90th percentiles with central bar representing
median).
(C–F) Cortical cells from WT or AMPKa1 KO ani-
mals were cultured for 20 DIV and then treated
with Ab42 oligomers or INV42 (1 mM for 24 hr). (C)
AMPKa activation (phosphorylation of T172 of
AMPKa1 and AMPKa2) and total AMPKa protein
level were assessed by western blotting (n = 9–11
animals per genotype). (D) Ab42 oligomers
increased AMPK phosphorylation in WT cells,
whereas oligomers had no effects in AMPKa1-
deficient cells. (E and F) Phosphorylation of Tau on
S262 and total Tau were assessed by western
blotting (n = 9–10 animals per genotype). Ab42
oligomers increased phosphorylation of Tau on
S262 in WT cells, whereas no effect was detected
in AMPKa1-deficient cells. Histograms in (D) and
(F) represent mean with SEM.
Statistical analysis was performed using ANOVA
test followed by Dunnett’s post hoc test in (B), and
paired t test in (D) and (F). *p < 0.05; **p < 0.01.
Scale bar, 1 mm (A).
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CAMKK2-AMPK Kinase Pathway and Alzheimer’s Diseasetauopathies, amyotrophic lateral sclerosis, and Huntington’s
disease (Ju et al., 2011; Lim et al., 2012; Vingtdeux
et al., 2011b). Whether activation of AMPK in these different
pathological contexts has a neuroprotective or deleterious
outcome in various neuronal subtypes remains controversial
(Salminen et al., 2011). Here, we demonstrate that activation of
AMPK, either pharmacologically or following overexpression of
AMPKa, is sufficient to trigger dendritic spine loss in mature hip-
pocampal neurons. Overexpression of CAMKK2 had a similar
negative effect on spine density, presumably by increasing cal-
cium sensitization and AMPK activity. The CAMKK2-AMPK
pathway appears critical with regard to AD pathology since its
blockade mitigates the synaptotoxic effects of Ab oligomers
in vitro and blocks the dendritic spine loss observed in the APPS-
WE,IND mouse model in vivo.
AMPK activity is increased in the hippocampus of the J20
transgenic mouse model as early as 4 months of age, a timeNeuron 78, 94–1when Ab oligomer levels are high and
signs of hippocampal network dysfunc-
tion already detectable (Palop et al.,
2007). Similarly, AMPK activity is
increased in the brain of other AD mouse
models such as the double APP/PS2 or
APPsw/PS1 dE9 mutants at 6 months
(Lopez-Lopez et al., 2007; Son et al.,2012), supporting a link between Ab oligomers and AMPKactiva-
tion. In agreement with these results, we found that 1 mM Ab42
oligomer exposure for 24 hr significantly increased AMPK activ-
ity in mature cortical cells, confirming previous studies by Thorn-
ton et al. (2011). Whether Ab42 oligomers can activate other
members of the AMPK-like family is still unclear, although recent
studies report that acute treatment of Ab42 oligomers does not
activate BRSK2 or MARK3 in primary hippocampal neurons
(Thornton et al., 2011).
Many kinases can act as direct upstream activators of AMPK,
including LKB1 (Hawley et al., 2003; Shaw et al., 2004),
CAMKK2, to a lesser extent CAMKK1 (Anderson et al., 2008;
Green et al., 2011; Hawley et al., 2005; Hurley et al., 2005;Woods
et al., 2005), and TAK1 (Momcilovic et al., 2006). We show
that Ab42 oligomer-induced activation of AMPK depends on
CAMKK2 in mature synaptically active cortical cultures. Impor-
tantly, AMPK is the only member of the AMPK-like family known08, April 10, 2013 ª2013 Elsevier Inc. 103
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the family are presumably not (Bright et al., 2008; Fogarty et al.,
2010). Thus, AMPK may represent the main member of this
family that responds to increased intracellular calcium medi-
ated by NMDAR activation and/or membrane depolarization.
Ab42 oligomer-induced activation of AMPK through CAMKK2
supports the hypothesis that Ab oligomers may disrupt calcium
homeostasis (Demuro et al., 2005; Mattson et al., 1992). Prefer-
ential targets of Ab42 oligomers are dendritic spines (Lacor et al.,
2004; Lacor et al., 2007), where they interfere with NMDAR
signaling to trigger rise in cytoplasmic calcium (De Felice et al.,
2007). Our results provide a mechanism whereby increased
neuronal excitation activates the CAMKK2-AMPK pathway lead-
ing to Tau phosphorylation on S262 and compromises spine
stability. In line with this hypothesis, (1) acute exposure of
neuronal cultures to Ab oligomers leads to local calcium level
increase, hyperphosphorylation, and mislocalization of Tau into
dendritic spines, which was associated with spine collapse
(De Felice et al., 2008; Zempel et al., 2010); and (2) Tau phos-
phorylation mediates dendritic spine collapse upon overexpres-
sion of AMPK-related MARK/PAR-1 in hippocampal neurons (Yu
et al., 2012).
Because of high similarity in their substrate specificity (Mihay-
lova and Shaw, 2011), most AMPK-related members might be
able to directly phosphorylate Tau on S262 (Yoshida and
Goedert, 2012). We have previously shown that BRSK1/
BRSK2 (also called SAD-A/B) can potently phosphorylate Tau
on S262 (Barnes et al., 2007). We now show that AMPK can
robustly phosphorylate Tau, confirming a previous report by
Thornton et al. (2011). Furthermore, AMPK is abnormally acti-
vated in tangle- and pretangle-bearing neurons in AD and
several tauopathies in humans (Vingtdeux et al., 2011b), sug-
gesting that AMPK may phosphorylate Tau in pathological con-
ditions. We found that AMPK increased phosphorylation of Tau
mainly on S262 in the microtubule-binding domain in primary
mature neurons, whereas other sites such as S356, S396, and
S422 were unaffected. Phosphorylation of other sites, S202/
Thr205 and S404, was decreased, suggesting the implication
of phosphatases or the negative regulation of the activity of
other kinases by AMPK. Furthermore, preventing phosphoryla-
tion at Tau S262 prevented the toxic effects of Ab oligomers in
hippocampal neurons. Therefore, activation of the CAMKK2-
AMPK pathway might converge on S262 of Tau to trigger dele-
terious effects on spine integrity. Alaninemutation of S262 in Tau
has also been reported to be protective in a fly model of AD
overexpressing human Ab42 or MARK/PAR-1 kinase that can
phosphorylate Tau at S262 (Chatterjee et al., 2009; Iijima
et al., 2010; Nishimura et al., 2004). The mechanisms underlying
Tau S262A protection against Ab42-mediated synaptotoxicity
are still unclear. There is growing recognition that Ab42 oligo-
mers induce Tau relocation from the axon to dendrites (Zempel
et al., 2010), where it can act as a protein scaffold to facilitate the
interaction of the Src kinase Fyn with NMDAR. This stabilizes
NMDAR to the postsynaptic density and couples the receptor
to excitotoxic downstream signaling, representing a potential
mechanism by which phosphorylated Tau could mediate Ab42
oligomer synaptotoxicity (Ittner et al., 2010). Removing Tau or
preventing Tau/Fyn interaction would uncouple excitotoxic104 Neuron 78, 94–108, April 10, 2013 ª2013 Elsevier Inc.downstream signaling (Ittner et al., 2010; Roberson et al.,
2007, 2011). Tau phosphorylation of its KxGS motifs (S262
and S356) in the microtubule-binding domains is thought
to act as a priming site for other phosphorylation sites and
globally controls Tau solubility by decreasing microtubule
affinity (Waxman and Giasson, 2011).
According to our results, impinging on the CAMKK2-AMPK
pathway may be of therapeutic value to lessen the synaptotoxic
effects of Ab42 oligomers. A previous study already targeted this
pathway in the hypothalamus to efficiently protect mice from
high-fat diet-induced obesity using intraventricular infusion of
the CAMKK2 inhibitor STO-609 (Anderson et al., 2008). It will
be of interest to determine if such treatment would protect
neurons from Ab toxicity in mouse models of AD and determine
if these protective effects ameliorate long-term behavioral
outcomes in the context of spatial learning for example.
Epidemiological and clinical studies identified type 2 diabetes
as a major risk factor for developing AD (Hassing et al., 2002;
MacKnight et al., 2002). Metformin is a widely prescribed
insulin-sensitizing drug and a potent activator of AMPK (Hundal
et al., 2000; Zhou et al., 2001). A recent study suggested that
metformin increases the generation of Ab40 and Ab42 through
upregulation of b secretase activity in an AMPK-dependent
manner (Chen et al., 2009). The authors also reported that a small
but significant amount of metformin crosses the blood-brain
barrier when administered to the drinking water in rodents.
Together with our present observations, long-term metformin
treatments could potentially have deleterious effects on AD pro-
gression in the central nervous system. Future investigations
should examine the effects of long-term metformin treatments
on symptom progression in various AD and obesity/type 2 dia-
betes mouse models in vivo.EXPERIMENTAL PROCEDURES
Animals
Mice were used according to protocols approved by the Institutional Animal
Care and Use Committee at Scripps Research Institute and in accordance
with National Institutes of Health guidelines. 129/SvJ, C57Bl/6J nontransgenic
mice and hemizygous transgenic mice from line J20 (hereafter referred as J20)
(The Jackson Laboratory) were maintained in a 12 hr light/dark cycle. J20mice
express human APP carrying the Swedish and Indiana mutations under
PDGFb promoter (Mucke et al., 2000; Palop et al., 2007). Constitutive AMPKa1
KO mice (Prkaa1tm1Vio) (Viollet et al., 2003) were a kind gift from Dr. Benoit
Viollet (INSERM, Institut Cochin, Paris). Constitutive CAMKK2 KO mice
(Ageta-Ishihara et al., 2009) were obtained from Dr. Talal Chatila (Harvard
Medical School, Boston). Timed-pregnant females were obtained by overnight
breeding with males of the same strain. Noon following breeding was consid-
ered as E0.5.
Ab42 Oligomer Preparation
Ab42 (rPeptide) was processed to generate Ab42 oligomers as described
previously by Klein (2002). Briefly, Ab42 was dissolved in hexafluoro-2-
propanol (HFIP; Sigma-Aldrich) for 2 hr to allow monomerization. HFIP was
removed by speed vacuum, and Ab42 monomers were stored at 80C.
Ab42monomers were dissolved in anhydrous DMSO tomake a 5mMsolution,
then added to cold phenol red-free F12 medium (Invitrogen) to make a 100 mM
solution. This solution was incubated at 4C for 2 days and then centrifuged at
14,000 3 g for 15 min in order to discard fibrils. The supernatant containing
Ab42 oligomers was assayed for protein content using the BCA kit (Pierce).
For control, a peptide corresponding to the inverted sequence of Ab42
Neuron
CAMKK2-AMPK Kinase Pathway and Alzheimer’s Disease(INV42; Bachem) was used and processed as for Ab42 oligomerization. Oligo-
merization of Ab42 was monitored by western blotting using 16.5% Tris-Tri-
cine gels (Bio-Rad) and the previously characterized 6E10 antibody (Chromy
et al., 2003).
Primary Neuronal Culture and Magnetofection
Cortices and hippocampi from E17.5 to E18.5 embryos were dissected in
Hank’s balanced salt solution (HBSS) supplemented with HEPES (10 mM)
and glucose (0.66M; Sigma-Aldrich). Tissues were dissociated in papain (Wor-
thington) supplemented with DNase I (100 mg/ml; Sigma-Aldrich) for 20 min at
37C, washed three times, and manually triturated in plating medium. Cells
were then plated at 565 cells/mm2 on glass-bottom dishes coated with poly-
D-lysine (1 mg/ml; Sigma-Aldrich) and cultured in neurobasal medium supple-
mented with 2.5% fetal bovine serum (Gemini), B27 (13), L-glutamine (2 mM),
and penicillin (2.5 U/ml)-streptomycin (2.5 mg/ml) (Invitrogen). At 5 DIV, half of
the medium was replaced with serum-free medium, and one-third of the me-
dium was then changed every 5 days. At 7 DIV, 5-Fluoro-50-deoxyuridine
(Sigma-Aldrich) was added to the culture medium at a final concentration of
5 mM to limit glia proliferation. Cells were maintained at 37C in 5% CO2 for
18–22 days. Neurons were transfected at 11 or 15 DIV by magnetofection us-
ing NeuroMag (OZ Bioscience), according to manufacturer’s instructions. Co-
transfections were performed at a 1:1 ratio (w/w). Briefly, cDNA (2 mg final) was
incubated with NeuroMag in neurobasal medium for 15 min at room tempera-
ture and then the mixture was applied dropwise on culture cells. Cultures were
placed on amagnet for 20min for transfection (see Supplemental Information).
Electrophysiology
Cell recordings were performed using a multiclamp 700B amplifier
(Axon Instruments). Neurons were recorded in a bath solution containing
140 mM NaCl, 5 mM KCl, 0.8 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, and
10 mM glucose. The whole-cell internal solution contained 135 mM CsCl2,
10 mM HEPES, 1 mM EGTA, 4 mM Na-ATP, and 0.40 mM Na-GTP. Sponta-
neous mEPSCs were isolated by adding 0.2 mM picrotoxin and 0.1 mM
tetrodotoxin in the recording bath solution and sampled in voltage-clamp
configuration using pClamp 10 (Axon Instruments). Analyses were done offline
using Clampfit 10 (Axon Instruments) and Excel (Microsoft). For illustration
purpose, traces were filtered at 200 Hz to remove noise. There were no differ-
ences in membrane capacitance (Cm) or input resting membrane resistance
(Rm) among experimental groups: CONT (control, EGFP only), Cm = 71.12 ±
5.9 pF and Rm = 117.62 ± 7.2 MU (n = 16); CONT+Ab42, Cm = 68.50 ± 4.4
pF and Rm = 105.28 ± 7.8 MU (n = 21); CAMKK2 KD, Cm = 67.66 ± 4.0 pF
and Rm = 103.31 ± 8.2 MU (n = 18); and CAMKK2 KD+Ab42, Cm = 83.95 ±
7.0 pF and Rm = 113.01 ± 8.0 MU (n = 16).
In Utero Electroporation
In utero electroporation was performed as previously described by Yi et al.
(2010) with slight modifications in order to target the embryonic hippocampus
(see Supplemental Information).
Image Acquisition and Analyses
Images were acquired in 1,024 3 1,024 resolution with a Nikon Ti-E micro-
scope equipped with the A1R laser-scanning confocal microscope using
the Nikon software NIS-Elements (Nikon, Melville, NY, USA). We used the
following objective lenses (Nikon): 103 PlanApo; NA 0.45 (for images of
cortical slices), 603 Apo TIRF; NA 1.49 (for analyses of spine densities in
cultured neurons), 1003 H-TIRF; and NA 1.49 (for analyses of spine densities
in brain slices). Dendritic spine density was quantified on secondary dendritic
branches that were proximal to the cell body, on z projections for cultured neu-
rons and in the depth of the z stack for slices, using FiJi software (ImageJ; NIH)
(see Supplemental Information).
Cell and Tissue Lysis and Western Blotting
Cultured cells or brain tissues were lysed in RIPA buffer (1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 150 mM NaCl in 50 mM Tris buffer [pH 8])
supplemented with benzonase (0.25 U/ml of lysis buffer; Novagen), and
cocktails of protease (Roche) and phosphatase (Sigma-Aldrich) inhibitors.
Equal amounts of lysates (20–50 mg) were loaded on a Mini-Protean TGX(4%–20%) SDS-PAGE (Bio-Rad). The separated proteins were transferred
onto polyvinylidene difluoride membranes (Amersham). For phospho-specific
antibodies, the membranes were blocked for 1 hr with blocking buffer contain-
ing 5% BSA in Tris-buffered saline solution and Tween 20 (10 mM Tris-HCl
[pH 7.4], 150 mM NaCl, 0.05% Tween 20; TBS-T). For other antibodies, mem-
branes were blocked for 1 hr with blocking buffer containing 5% fat-free dry
milk in TBS-T. Membranes were then incubated overnight at 4Cwith different
primary antibodies diluted in the same blocking buffer. Incubations with HRP-
conjugated secondary antibodies were performed for 1 hr at room tempera-
ture, and visualization was performed by quantitative chemiluminescence
using Fluorochem Q imager (ProteinSimple). Signal intensity was quantified
using AlphaView software (ProteinSimple). Antibodies were the following:
anti-phospho-T172-AMPKa (40H9, 1:1,000; Cell Signaling); AMPKa1/2
(1:1,000; Cell Signaling); AMPKa1 (1:1,000; Abcam); CAMKK2 (1:1,000; Santa
Cruz Biotechnology); phospho-Tau (S262, S356, S396, S404, and S422,
1:1,000; Invitrogen); phospho-PHF-Tau (S202/Thr205, AT8, 1:1,000; Pierce);
Tau5 (1:1,000; Invitrogen); mouse monoclonal anti-GFP (1:2,000; Roche);
and anti-Myc (1:5,000, 9E10; Cell Signaling). Human APP and Ab were
detected by western blotting using 12% Tris-Glycine and 16.5% Tris-Tricine
gels (Bio-Rad), respectively, and the anti-human APP/Ab 6E10 antibody
(1:1,000; Covance). To control for loading, blots were stripped and reprobed
with mouse monoclonal anti-actin (1:5,000; Millipore).
Statistics
Statistical analyses were performed with Prism 6 (GraphPad Software). The
statistical test applied for data analysis is indicated in the corresponding figure
legend. The normality of the distributions of values obtained for each group/
experimental treatment was determined using the Kolmogorov-Smirnov test.
Experimental groups where all distributions were Gaussian/normal were
assessed using the unpaired t test for two-population comparison, or one-
way ANOVA with Dunnett’s post hoc test for multiple comparisons. Nonpara-
metric tests including theMann-Whitney U test for two-population comparison
and Kruskal-Wallis with Dunn’s posttest for multiple comparisons were
applied when distributions were not Gaussian. Unless otherwise noted, data
are expressed as mean ± SEM. For dendritic spine analysis, all data were
obtained from at least three independent experiments or at least three indi-
vidual mice. The test was considered significant when p < 0.05. For all
analyses, the following apply: *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001; ns, not significant p > 0.05. For clarity purpose, the color of the marker
(asterisk [*] or ‘‘ns’’) refers to the corresponding condition used for statistical
comparison.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2013.02.003.
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